|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired
|
gptkb:Genzyme
gptkb:Aventis
|
|
gptkbp:acquisition
|
gptkb:Amunix_Pharmaceuticals
gptkb:Bioverativ
gptkb:Kymab
gptkb:Medi_Gene_AG
Translate Bio
|
|
gptkbp:ceo
|
gptkb:Paul_Hudson
|
|
gptkbp:employees
|
around 100,000
|
|
gptkbp:founded
|
gptkb:2004
|
|
gptkbp:headquarters
|
gptkb:Paris,_France
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi Aventis
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Paul_Hudson
|
|
gptkbp:market_cap
|
€100 billion (2021)
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Regeneron_Pharmaceuticals
gptkb:Moderna
gptkb:Regeneron
|
|
gptkbp:product
|
gptkb:pharmaceuticals
gptkb:Ambien
gptkb:Dupixent
gptkb:Lantus
gptkb:Cerdelga
gptkb:Plavix
gptkb:Aubagio
gptkb:Praluent
gptkb:Toujeo
gptkb:Zaltrap
gptkb:Cablivi
gptkb:Thymoglobulin
Allegra
Eloxatin
Lovenox
Admelog
Jevtana
Sarclisa
Xyzal
|
|
gptkbp:products
|
gptkb:diabetes
antibiotics
vaccines
|
|
gptkbp:research_focus
|
gptkb:diabetes
oncology
rare diseases
vaccines
|
|
gptkbp:revenue
|
€36.1 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:Euronext_Paris
|
|
gptkbp:subsidiary
|
gptkb:Sanofi_Genzyme
gptkb:Sanofi_Pasteur
|
|
gptkbp:type
|
gptkb:Corporation
|
|
gptkbp:website
|
www.sanofi.com
|
|
gptkbp:bfsParent
|
gptkb:Sanofi
|
|
gptkbp:bfsLayer
|
4
|